Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Early intravenous beta blockers improve risk of ventricular tachyarrhythmias in subjects with acute coronary syndrome [Meeting Abstract]

Chatterjee S.; Nerella N.; Mukherjee D.; Bangalore S.; Lichstein E.
Background: Intravenous (IV) Beta-blockade is currently not routinely recommended in the early management of patients with acute coronary syndromes (ACS)-even for patients without obvious contraindications. We performed a systematic review of the medical literature to determine if early IV beta-blockade improves the risk of in-hospital ventricular tachyarrhythmias (ventricular tachycardia/fibrillation) in patients with ACS. Methods: The authors searched the PubMed and EMBASE databases for randomized controlled trials and controlled clinical trials from 1965 through 2009. Intervention included intravenous beta-blockers administered within 24 hours of presentation. The comparator included standard medical therapy and/or placebo. The outcome assessed was the risk of development of in-hospital ventricular tachyarrhythmias (both Vtach and Vfib) in the intervention groups versus the comparator groups. The methodological quality of the studies was assessed. In-hospital mortality rates were compared using a forest plot of relative risk (RR; 95% confidence interval [CI]) using a random effect model (Mantel-Haenszel) between beta-blockers and controls. Statistical analysis was done with Review Manager V5.0. Results: Thirteen studies (total N = 114,801) met the inclusion/ exclusion criteria. In-hospital development of ventricular tachycardia/ fibrillation was reduced 1.88% (7.46% Vs 5.58%) with IV beta-blockers, RR = 0.56 (95% CI, 0.46-0.68; p<0.01). Conclusions: This systematic review suggests a benefit with early use of IV beta-blockers in appropriate patients with ACS for preventing development of ventricular tachyarrhythmias. (Table Presented)
EMBASE:70413946
ISSN: 1522-1946
CID: 132601

Femoral arterial access and closure

Bangalore, Sripal; Bhatt, Deepak L
PMID: 21810667
ISSN: 1524-4539
CID: 137839

When conventional heart failure therapy is not enough: Angiotensin receptor blocker or aldosterone antagonist? [Meeting Abstract]

Bangalore S.; Kumar S.; Messerli F.H.
Background: Recent clinical trials suggest that in patients already on conventional heart failure therapy the addition of angiotensin receptor blockers (ARBs) or aldosterone antagonists (AA) are reasonable therapeutic options to further reduce the risk of cardiovascular events. However, whether one is preferable over the other is unknown. Methods: PUBMED, EMBASE,and CENTRAL were searched for randomized clinical trials (RCTs), of trials testing either an ARB or an AA in patients with heart failure and reduced systolic function who were on conventional heart failure therapy (including diuretics,beta blockers and angiotensin converting enzyme inhibitors (ACEi)) with follow-up of at least 6-months. Efficacy (death, cardiovascular (CV) death, myocardialinfarction, stroke, heart failure hospitalization, CV death or heart failure hospitalization) and safety (hyperkalemia, hypotension, renal failure) outcomes were compared. Results: We identified 12 RCTs involving 29,514 participants that satisfied our inclusion criteria. When compared with placebo (reference rate ratio 1), the addition of aldosterone antagonists reduced death from all causes (rate ratio (RR) = 0.80, 95% Credibility Interval (CrI)0.64-0.97), cardiovascular death (RR = 0.79; 95% CrI 0.65-0.94) and heart failure hospitalization (RR = 0.73; 95% CrI 0.56- 0.93) with no difference for other efficacy outcomes. In contrast, the addition of ARBs did not significantly reduce the rate of any of the efficacy outcomes when compared with placebo. Moreover, ARBs but not AA increased the rate of hyper- (Figure presented) hyperkalemia (138% increase), renal failure (126% increase) and hypotension (63% increase). Conclusions: In patients with heart failure and reduced systolic function on conventional medications including ACEi, the risk-benefit ratio favors AA over ARBs
EMBASE:70536012
ISSN: 0195-668x
CID: 137908

Heart rate in patients with coronary artery disease - the lower the better? An analysis from the Treating to New Targets (TNT) trial [Meeting Abstract]

Bangalore S.; Wun C.C.; Demicco D.; Breazna A.; Deedwania P.; Messerli F.H.
Background: In patients post myocardial infarction and in those with established coronary artery disease (CAD), lower heart rate has been shown to improve long term cardiovascular prognosis. However, how low is low enough and the existence of J-curve relationship has not been proven. Methods: We evaluated 9602 patients, with CAD and a LDL cholesterol level <130 mg/dL, randomized to atorvastatin 80 mg vs. 10 mg, enrolled in the TNT trial. The post-baseline, time-dependent heart rate were categorized into 10 mm Hg increments. The primary outcome was a composite of death from coronary disease, nonfatal myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. Results: Among the 9602 patients, 886 (9.23%) experienced a primary outcome at 4.9 years (median) of follow-up. The relationship between heart rate and primary outcome followed a J-curve with increased event rates above and below the reference heart rate range, both unadjusted and adjusted (for baseline covariates, treatment effect and LDL levels). A time-dependent, non-linear, multivariate Cox proportional hazard (PH) model identified a nadir of 52.4 bpm where the event rate was lowest (Figure). Similar, non-linear relationship, with higher risk of events at lower heart rate was found for most of the secondary outcomes of all-cause mortality, CV mortality, nonfatal MI, or stroke. (Figure presented) Conclusions: In patients with CAD, a very low heart rate portends an increased risk of future cardiovascular events
EMBASE:70534318
ISSN: 0195-668x
CID: 137911

The presence, characterization and prognosis of coronary plaques among patients with zero coronary calcium scores

Uretsky, Seth; Rozanski, Alan; Singh, Padmakshi; Supariwala, Azhar; Atluri, Prashanth; Bangalore, Sripal; Pappas, Thomas W; Fisher, Edward A; Peters, M Robert
Patients with coronary artery calcium (CAC) scores of zero are generally considered not to have atherosclerosis. Recent studies involving computed tomography coronary angiography (CTCA) challenge this assumption. This goal of the present study is to assess the frequency, morphology, location, and the prognosis of patients with plaque detected on CTCA and zero CAC. 1,119 patients (51 +/- 12 years, 52% male) with a zero CAC score during CTCA study were retrospectively identified. The CTCA studies were assessed for the presence, morphology, location and severity of all coronary plaques. All-cause mortality was assessed. The prevalence of coronary plaque was 13% (147 patients). Among the 212 plaques identified 154 (73%) were non-calcified, 28 (13%) were calcified, and 30 (14%) were of mixed morphology. Notably, >/=70% stenosis was noted among only 0.4% of all patients. ROC analysis revealed that coronary artery disease risk factors did not add to the prediction of plaque among our patients. Over a mean follow-up of 2.5 +/- 0.6 years there were 4 deaths (0.4%), all in patients without coronary plaque on CTCA. The presence of coronary plaque is not uncommon among patients with zero CAC scores. These plaques were rarely associated with hemodynamically significant stenoses and were associated with an excellent prognosis. Clinical factors do not appear to be useful in predicting which patients with zero CAC scores have undetected coronary plaque
PMID: 20967569
ISSN: 1875-8312
CID: 138329

Review: Angiotensin-receptor blockers do not increase adverse cardiovascular outcomes [Note] [Comment]

Bangalore S.
EMBASE:2011448481
ISSN: 0003-4819
CID: 139486

Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry

Bangalore, Sripal; Cohen, David J; Kleiman, Neal S; Regev-Beinart, Tal; Rao, Sunil V; Pencina, Michael J; Mauri, Laura
BACKGROUND: Prior randomized trials have shown reduced bleeding with bivalirudin compared with unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention (PCI). However, it is not known if this benefit is also present when UFH doses are more tightly controlled (as measured by activated clotting time, ACT). METHODS AND RESULTS: Patients enrolled in the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry, were divided into 3 groups, based on the antithrombotic drug used during PCI (UFH monotherapy, UFH+glycoprotein IIb-IIIa receptor inhibitor [GPI], or bivalirudin alone). Propensity score matching was used to adjust for measured covariates (89 variables) and to compare bivalirudin versus UFH monotherapy and bivalirudin versus UFH+GPI groups. The UFH groups were stratified based on ACT achieved (optimal ACT defined as 250-300 for UFH monotherapy and 200-250 when GPI was also used). The primary bleeding outcome was in-hospital composite bleeding, defined as events of access site bleeding, Thrombolysis In Myocardial Infarction major/minor bleeding, or transfusion. Primary (in-hospital death/myocardial infarction) and secondary ischemic outcomes (death/MI/unplanned repeat revascularization at 12 months) were also evaluated. Propensity score matching yielded 3022 patients for the UFH monotherapy versus bivalirudin comparison and 3520 patients for the UFH+GPI versus bivalirudin comparison. Bivalirudin use was associated with numerically lower bleeding rates at all categories of achieved ACT when compared with UFH (low, optimal, high ACT: 2.5% versus 4.7%, 1.9% versus 6.0%, 3.1% versus 4.8%, respectively) or heparin+GPI groups (low, optimal, high ACT: 0.0% versus 2.7%, 2.7% versus 5.2%, 2.4% versus 6.1%, respectively) and was not associated with any statistically significant increase in either primary or secondary ischemic outcomes. CONCLUSIONS: Among unselected patients undergoing PCI, bivalirudin use during PCI was associated with a lower risk of bleeding at all comparator ACT levels without an increase in ischemic outcomes
PMID: 21972401
ISSN: 1941-7632
CID: 141969

Images in cardiovascular medicine. Right heart catheterization, coronary angiography, and percutaneous coronary intervention

Bangalore, Sripal; Bhatt, Deepak L
PMID: 22025641
ISSN: 1524-4539
CID: 141973

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions

Mauri, Laura; Kereiakes, Dean J; Normand, Sharon-Lise T; Wiviott, Stephen D; Cohen, David J; Holmes, David R; Bangalore, Sripal; Cutlip, Donald E; Pencina, Michael; Massaro, Joseph M
BACKGROUND: Dual antiplatelet therapy with aspirin and thienopyridines (clopidogrel or prasugrel) is required after placement of coronary stents to prevent thrombotic complications. Although current clinical practice guidelines recommend 12-month treatment after drug-eluting stent placement, even longer durations may prevent thrombotic events. STUDY DESIGN: The Dual Antiplatelet Therapy (DAPT) Study is comparing the benefits and risks of 12 versus 30 months of dual antiplatelet therapy in preventing stent thrombosis or major adverse cardiovascular and cerebrovascular events in subjects undergoing percutaneous coronary intervention (PCI) for the treatment of coronary artery obstructive lesions. The DAPT Study is a multicenter, international, randomized, double-blind, placebo-controlled trial that will enroll 15,245 subjects treated with drug-eluting stent (DES) and 5,400 subjects treated with bare-metal stents (BMS). All subjects will receive 12 months of open-label thienopyridine treatment in addition to aspirin. After 12 months, subjects who are free from death, myocardial infarction, or stroke (MACCE), repeat revascularization, and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) moderate or severe bleeding events will be randomized to receive either 18 additional months of thienopyridine (clopidogrel or prasugrel) (30 month DAPT arm) or placebo (12 month DAPT arm) plus aspirin. Coprimary end points are MACCE and stent thrombosis. The primary safety end point is GUSTO moderate or severe bleeding. CONCLUSIONS: This randomized trial is designed to define the relative safety and effectiveness of 12 versus 30 months of dual antiplatelet therapy across the broad spectrum of patients receiving coronary stents.
PMID: 21146655
ISSN: 0002-8703
CID: 218662

Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference

Bangalore, Sripal; Kumar, Sunil; Messerli, Franz H
BACKGROUND: Dry cough is a common, annoying adverse effect of all angiotensin-converting enzyme (ACE) inhibitors. The present study was designed to compare the rate of coughs reported in the literature with reported rates in the Physicians' Desk Reference (PDR)/drug label. METHODS: We searched MEDLINE/EMBASE/CENTRAL for articles published from 1990 to the present about randomized clinical trials (RCTs) of ACE inhibitors with a sample size of at least 100 patients in the ACE inhibitors arm with follow-up for at least 3 months and reporting the incidence or withdrawal rates due to cough. Baseline characteristics, cohort enrolled, metrics used to assess cough, incidence, and withdrawal rates due to cough were abstracted. RESULTS: One hundred twenty-five studies that satisfied our inclusion criteria enrolled 198,130 patients. The pooled weighted incidence of cough for enalapril was 11.48% (95% confidence interval [CI], 9.54% to 13.41%), which was ninefold greater compared to the reported rate in the PDR/drug label (1.3%). The pooled weighted withdrawal rate due to cough for enalapril was 2.57% (95% CI, 2.40-2.74), which was 31-fold greater compared to the reported rate in the PDR/drug label (0.1%). The incidence of cough has increased progressively over the last 2 decades with accumulating data, but it has been reported consistently several-fold less in the PDR compared to the RCTs. The results were similar for most other ACE inhibitors. CONCLUSION: The incidence of ACE inhibitor-associated cough and the withdrawal rate (the more objective metric) due to cough is significantly greater in the literature than reported in the PDR/drug label and is likely to be even greater in the real world when compared with the data from RCTs. There exists a gap between the data available from the literature and that which is presented to the consumers (prescribing physicians and patients).
PMID: 21035591
ISSN: 0002-9343
CID: 218672